William Blair Cuts Earnings Estimates for Keros Therapeutics

Keros Therapeutics, Inc. (NASDAQ:KROS) – William Blair reduced their FY2024 earnings estimates for Keros Therapeutics in a research report issued to clients and investors on Wednesday, November 6th. William Blair analyst M. Phipps now expects that the company will earn ($5.17) per share for the year, down from their previous forecast of ($5.00). The consensus estimate for Keros Therapeutics’ current full-year earnings is ($5.14) per share. William Blair also issued estimates for Keros Therapeutics’ Q4 2024 earnings at ($1.30) EPS, Q1 2025 earnings at ($1.23) EPS, Q2 2025 earnings at ($1.18) EPS, Q3 2025 earnings at ($0.98) EPS, Q4 2025 earnings at ($0.77) EPS, FY2025 earnings at ($4.16) EPS, FY2026 earnings at ($3.47) EPS and FY2027 earnings at ($3.15) EPS.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company had revenue of $0.39 million for the quarter. During the same quarter last year, the firm earned ($1.33) EPS. The company’s revenue for the quarter was up 4750.0% on a year-over-year basis.

KROS has been the topic of a number of other research reports. Scotiabank initiated coverage on shares of Keros Therapeutics in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 price objective on the stock. HC Wainwright restated a “buy” rating and issued a $100.00 price target on shares of Keros Therapeutics in a research note on Thursday, November 7th. Jefferies Financial Group assumed coverage on Keros Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating for the company. Guggenheim initiated coverage on Keros Therapeutics in a research report on Monday, September 23rd. They issued a “buy” rating and a $96.00 target price on the stock. Finally, Cantor Fitzgerald assumed coverage on Keros Therapeutics in a research report on Thursday, October 24th. They set an “overweight” rating for the company. Twelve equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $88.89.

Keros Therapeutics Price Performance

Shares of NASDAQ KROS opened at $68.15 on Monday. The firm has a market capitalization of $2.56 billion, a PE ratio of -13.08 and a beta of 1.23. Keros Therapeutics has a 1-year low of $27.31 and a 1-year high of $73.00. The business’s fifty day moving average price is $58.65 and its two-hundred day moving average price is $52.23.

Institutional Trading of Keros Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of KROS. Vanguard Group Inc. grew its holdings in Keros Therapeutics by 7.9% during the first quarter. Vanguard Group Inc. now owns 1,545,758 shares of the company’s stock worth $102,329,000 after acquiring an additional 113,563 shares during the period. Darwin Global Management Ltd. grew its stake in shares of Keros Therapeutics by 6.3% in the 2nd quarter. Darwin Global Management Ltd. now owns 1,525,902 shares of the company’s stock worth $68,772,000 after purchasing an additional 89,952 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Keros Therapeutics by 17.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,218,504 shares of the company’s stock worth $80,666,000 after purchasing an additional 176,803 shares in the last quarter. Redmile Group LLC acquired a new stake in Keros Therapeutics during the first quarter valued at approximately $36,576,000. Finally, Nantahala Capital Management LLC boosted its holdings in Keros Therapeutics by 28.8% during the second quarter. Nantahala Capital Management LLC now owns 378,807 shares of the company’s stock worth $17,311,000 after buying an additional 84,810 shares in the last quarter. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.